← All trials
NCT04022915
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2019
- Primary completion
- May 13, 2023
- Completion date
- May 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.